The North America tulathromycin market has witnessed significant growth in the past and is expected to grow at a CAGR of 4.2% during the forecast period (2022–2030). Bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs are both treatable with tulathromycin, a macrolide antibiotic. Pfizer Inc. sells it under the brand name Draxxin. The 100-mg dose is contained in an injectable solution.
The high prevalence of BRD and SRD drives the North American tulathromycin market. The North American entry of generic tulathromycin acts as a restraint on this market. On the other hand, a lucrative opportunity for new entrants in generic tulathromycin is an opportunity for the tulathromycin market.
BRD is the most common pathology in young and adult animals, affecting 20–25% of calves annually, 10% of which experience growth retardation and up to 6% die. Swine can also have an SRD prevalence rate of around 20%, with a mortality rate of up to 20% and a risk of sequelae in up to 40% of affected animals. Beyond the effects on animal health, BRD and SRD have a significant financial impact on the farmer because of the reduction in animal growth, the expense of diagnosis and treatment, mortality, and the cost of additional work.
Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine. Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves. Additionally, it's used to treat swine respiratory disease (SRD), which is a condition that affects swine and is brought on by pathogens like Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.
The approved brand-name drug product Draxxin, first approved in 2005, shares the same active component (tulathromycin) with Macrosyn and Increxxa in the same dose form and concentration. These two generic medications are anticipated to reduce the demand for tulathromycin in the next few years. By consuming some of the demand for the name-brand Draxxin, the demand for generic medicines will increase more quickly.
The formulation of Draxxin, which contains the active component tulathromycin, is protected by patents in the United States, Canada, and other important markets. The patent in the United States, Canada, and Australia expires in February 2021. Till 2023, the active component tulathromycin is protected in Japan. Products containing generic tulathromycin are sold in a few nations, including Colombia, Vietnam, Belarus, Russia, Poland, and Croatia. Marketing permits for products containing generic tulathromycin.
This provides the participants with a lucrative opportunity to enter the industry and take advantage of the growth opportunity, particularly in the United States and Europe. Due to the high end-user spending power and greater reliance on beef and dairy cattle, the U.S. and Europe are the two largest markets for the consumption of antibiotics for BRD and SRD. During the forecast period, we anticipate the arrival of numerous new players in the tulathromycin market in these two areas.
| Study Period | 2020-2032 | CAGR | 4.2% |
| Historical Period | 2020-2022 | Forecast Period | 2024-2032 |
| Base Year | 2023 | Base Year Market Size | USD XX Billion |
| Forecast Year | 2032 | Forecast Year Market Size | USD XX Billion |
The market is segmented based on country into the U.S., Canada, and Mexico. The U.S. dominates the country market and is expected to grow at a CAGR of 4.2% during the forecast period.
The biggest market for tulathromycin is North America. The region controls much of the market despite only containing 5% of the world's population. The United States holds a monopolistic position in regional and international markets. The number of cattle in the United States is above 94.4 million, somewhat fewer than in 2019. More than 98% of all beef cattle kept in feedlots have been found to contract the virus, and more than 45% of all feedlot fatalities are attributable to bovine respiratory disease. Accordingly, farmers are taking extra precautions to prevent the anticipated events and administering tulathromycin for the disease's prevention and treatment.
The number of swine in the United States has significantly increased recently. It has grown to 6 million as of 2020 and is likely to grow more.
The U.S. FDA recently approved Macrosyn and Increxxa, two generic tulathromycin medications. These medications are anticipated to have a positive CAGR in the years to come for branded tulathromycin medications.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The North American tulathromycin market is segmented based on animal and country.
Based on animals, the market is segmented into cattle and swine.
Cattle dominates the market and is expected to register a CAGR of 4.6% over the forecast period. For the treatment and prevention of bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cats, tulathromycin is used. In the U.S. cattle industry, BRD remains the leading cause of morbidity and mortality in feedlots, resulting in poor performance, carcass quality, and animal health losses. In the United States dairy industry, respiratory disease plays a significant role in weaned calf mortality, and morbidity due to BRD negatively impacts survivability and dairy performance later in life.
